Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not?

doi:10.1016/s0002-9440(10)63664-4

Comment

. 2003 Jul;163(1):373-5; author reply 375-6.

doi: 10.1016/s0002-9440(10)63664-4.

Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not?

Peter J van den Elsen, Nienke van der Stoep

PMID: 12819045
PMCID: PMC1868151
DOI: 10.1016/s0002-9440(10)63664-4

Comment

Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not?

Peter J van den Elsen et al. Am J Pathol. 2003 Jul.

. 2003 Jul;163(1):373-5; author reply 375-6.

doi: 10.1016/s0002-9440(10)63664-4.

Authors

Peter J van den Elsen, Nienke van der Stoep

PMID: 12819045
PMCID: PMC1868151
DOI: 10.1016/s0002-9440(10)63664-4

No abstract available

PubMed Disclaimer

Figures

**Figure 1.**
RT-PCR analysis on IFN-γ-inducible expression of promoter III-derived (Pro III) and promoter IV-derived (Pro IV) CIITA (38 cycles of PCR) and GAPDH (28 cycles of PCR) in small cell lung cancer (SCLC), neuroblastoma (NB), and non-SCLC cell lines. Cultured cancer cells were treated with 500 units/ml IFN-γ for 24 hours.

See this image and copyright information in PMC

Comment on

Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma.
Yazawa T, Ito T, Kamma H, Suzuki T, Okudela K, Hayashi H, Horiguchi H, Ogata T, Mitsui H, Ikeda M, Kitamura H. Yazawa T, et al. Am J Pathol. 2002 Jul;161(1):291-300. doi: 10.1016/S0002-9440(10)64181-8. Am J Pathol. 2002. PMID: 12107114 Free PMC article.

Cited by

Contrasting effects of IFNα on MHC class II expression in professional vs. nonprofessional APCs: Role of CIITA type IV promoter.
Pisapia L, Pozzo GD, Barba P, Citro A, Harris PE, Maffei A. Pisapia L, et al. Results Immunol. 2012 Sep 27;2:174-83. doi: 10.1016/j.rinim.2012.09.001. eCollection 2012. Results Immunol. 2012. PMID: 24371581 Free PMC article.
A Seven-Gene Signature with Close Immune Correlation Was Identified for Survival Prediction of Lung Adenocarcinoma.
Zou X, Hu Z, Huang C, Chang J. Zou X, et al. Med Sci Monit. 2020 Jul 2;26:e924269. doi: 10.12659/MSM.924269. Med Sci Monit. 2020. PMID: 32613949 Free PMC article.
Functional disruption of human leukocyte antigen II in human embryonic stem cell.
Chen H, Li Y, Lin X, Cui D, Cui C, Li H, Xiao L. Chen H, et al. Biol Res. 2015 Oct 27;48:59. doi: 10.1186/s40659-015-0051-6. Biol Res. 2015. PMID: 26506955 Free PMC article.

References

1. Yazawa T, Ito T, Kamma H, Suzuki T, Okudela K, Hayashi H, Horiguchi H, Ogata T, Mitsui H, Ikeda M, Kitamura H: Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma. Am J Pathol 2002, 161:291-300 - PMC - PubMed
1. Ostrand-Rosenberg S, Thakur A, Clements V: Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 1990, 144:4068-4071 - PubMed
1. Kamma H, Fujii K, Ogata T: Lymphocytic infiltration in juvenile thyroid carcinoma. Cancer 1988, 62:1988-1993 - PubMed
1. Yazawa, Kamma H, Ogata T: Frequent expression of HLA-DR antigen in medullary carcinoma of the breast: a possible reason for its prominent lymphocytic infiltration and favorable prognosis. Appl Immunohistochem 1993, 1:289-296
1. Yazawa T, Kamma H, Fujiwara M, Matsui M, Horiguchi H, Satoh H, Fujimoto M, Yokoyama K, Ogata T: Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol 1999, 187:191-199 - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources

[1] Yazawa T, Ito T, Kamma H, Suzuki T, Okudela K, Hayashi H, Horiguchi H, Ogata T, Mitsui H, Ikeda M, Kitamura H: Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma. Am J Pathol 2002, 161:291-300 - PMC - PubMed

[2] Yazawa T, Ito T, Kamma H, Suzuki T, Okudela K, Hayashi H, Horiguchi H, Ogata T, Mitsui H, Ikeda M, Kitamura H: Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma. Am J Pathol 2002, 161:291-300 - PMC - PubMed

[3] Ostrand-Rosenberg S, Thakur A, Clements V: Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 1990, 144:4068-4071 - PubMed

[4] Ostrand-Rosenberg S, Thakur A, Clements V: Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 1990, 144:4068-4071 - PubMed

[5] Kamma H, Fujii K, Ogata T: Lymphocytic infiltration in juvenile thyroid carcinoma. Cancer 1988, 62:1988-1993 - PubMed

[6] Kamma H, Fujii K, Ogata T: Lymphocytic infiltration in juvenile thyroid carcinoma. Cancer 1988, 62:1988-1993 - PubMed

[7] Yazawa, Kamma H, Ogata T: Frequent expression of HLA-DR antigen in medullary carcinoma of the breast: a possible reason for its prominent lymphocytic infiltration and favorable prognosis. Appl Immunohistochem 1993, 1:289-296

[8] Yazawa, Kamma H, Ogata T: Frequent expression of HLA-DR antigen in medullary carcinoma of the breast: a possible reason for its prominent lymphocytic infiltration and favorable prognosis. Appl Immunohistochem 1993, 1:289-296

[9] Yazawa T, Kamma H, Fujiwara M, Matsui M, Horiguchi H, Satoh H, Fujimoto M, Yokoyama K, Ogata T: Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol 1999, 187:191-199 - PubMed

[10] Yazawa T, Kamma H, Fujiwara M, Matsui M, Horiguchi H, Satoh H, Fujimoto M, Yokoyama K, Ogata T: Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol 1999, 187:191-199 - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not?

Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not?

Authors

Figures

Comment on

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources